- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03431857
Multi Centre Study on TESS V2 Shoulder System
September 21, 2021 updated by: Zimmer Biomet
Retrospective and Prospective, Multi Centre Study on T.E.S.S® V2 Shoulder System
This study is a Post Market Clinical Follow-up study to fulfill the post market surveillance requirements.
The data collected from this study will serve the purpose of confirming safety and performance of the TESS Shoulder System.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objective of this retrospective and prospective, multicenter, non-controlled Post Market Clinical Follow-up study is to evaluate the mid-term (5-year) clinical performance of the TESS Version 2 Anatomic and Reverse prostheses in shoulder arthroplasty.
The primary outcome is defined as the clinical performance determined using Constant Score.
The secondary outcomes are the passive and active mobility, the radiographic evaluation, the complications (including dislocation and revisions/removals) and survivorship.
Study Type
Observational
Enrollment (Actual)
106
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients in need of Total Shoulder Arthroplasty (primary or revision) who receive the TESS V2 and who meet all of the inclusion and none of the exclusion criteria.
Description
Inclusion Criteria:
Except in special cases, the "anatomic" type is indicated for:
- Centered osteoarthritis of the shoulder
- Humeral head fractures
- Rheumatoid arthritis (with intact rotator cuff)
- Avascular necrosis of the humeral head
Except in special cases, the "reversed" type is indicated for:
- Offset osteoarthritis of the shoulder
- Massive and non-repairable rotator cuff tears
- Rheumatoid arthritis (with degenerative rotator cuff)
Revision in cases of:
- Replacement of an "anatomic" prosthesis with a "reversed" prosthesis
- Conversion of a hemi-arthroplasty into a total arthroplasty
- Increasing the size of the stem (length and/or diameter)
- Replacing a glenoid prosthesis
- Replacing a competitor's prosthesis
- In rare cases, removing a "reversed" prosthesis and replacing it with an "anatomic" prosthesis
Additional inclusion criteria include
- Patient who read, understood study information and gave informed consent (oral or written depending on specific local regulatory requirements)
- Willing to return for follow-up evaluations
Exclusion Criteria:
- Local or systemic infections.
- Severe muscular, neurological, or vascular deficiency of the affected joint.
- Bone destruction or poor bone quality liable to affect the stability of the implant (Paget's disease, osteoporosis, etc.)
- Cases where the corolla cannot be two-thirds covered with bone stock and including the stem/corolla junction.
- Any concomitant complaint likely to affect the functioning of the implant.
- Allergy to any of the implant components.
- Local bone tumors.
- Patient over 18 under law supervision
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
TESS V2 Prosthesis
Single study patient cohort, including 106 patients who meet the inclusion/exclusion criteria and who received the TESS V2 shoulder prosthesis.
|
Patients requiring the TESS V2 prosthesis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Constant Shoulder Score
Time Frame: Pre-operative, 5 years follow-up
|
The Constant Murley score is a multi-item scale assessing the level of pain and the ability to carry out the normal daily activities of the patient.
The test is divided into four subscales: pain (0-15 points), activities of daily living (0-20 points), strength (0-25 points) and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder (0-40 points).
The results are here reported as final score, which ranges from 0 to 100, with 0 representing the worst and 100 the best shoulder function.
|
Pre-operative, 5 years follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Active Anterior Elevation
Time Frame: Pre-operative, 5 years follow-up
|
The active mobility is measured with 4 movements: active anterior elevation, active lateral elevation, external rotation elbow to body (RE 1) and external shoulder rotation in abduction at 90° (RE 2).
Active anterior elevation measures the extent to which a patient can elevate the arm anteriorly and is here reported in degrees.
|
Pre-operative, 5 years follow-up
|
Active Lateral Elevation
Time Frame: Pre-operative, 5 years follow-up
|
The active mobility is measured with 4 movements: active anterior elevation, active lateral elevation, external rotation elbow to body (RE 1) and external shoulder rotation in abduction at 90° (RE 2).
Active lateral elevation measures the extent to which a patient can elevate the arm laterally and is here reported in degrees.
|
Pre-operative, 5 years follow-up
|
Active External Rotation RE1
Time Frame: Pre-operative, 5 years follow-up
|
The active mobility is measured with 4 movements: active anterior elevation, active lateral elevation, external rotation elbow to body (RE 1) and external shoulder rotation in abduction at 90° (RE 2).
Active external rotation RE1 measures the extent to which a patient can rotate the bent arm externally and is here reported in degrees.
|
Pre-operative, 5 years follow-up
|
Active External Rotation RE2
Time Frame: Pre-operative, 5 years follow-up
|
The active mobility is measured with 4 movements: active anterior elevation, active lateral elevation, external rotation elbow to body (RE 1) and external shoulder rotation in abduction at 90° (RE 2).
Active external rotation RE2 measures the extent to which a patient can rotate the arm externally from a position of 90° of abduction and is here reported in degrees.
|
Pre-operative, 5 years follow-up
|
Passive Elevation
Time Frame: Pre-operative, 5 years follow-up
|
The passive mobility is measured with 2 movements: elevation and external rotation elbow to body (RE 1).
Passive elevation measures the extent to which the arm of the patient can be passively elevated in the plane of the scapula and is here reported in degrees.
|
Pre-operative, 5 years follow-up
|
Passive External Rotation
Time Frame: Pre-operative, 5 years follow-up
|
The passive mobility is measured with 2 movements: elevation and external rotation elbow to body (RE 1).
Passive external rotation elbow to body (RE 1) measures the extent to which the bent arm of the patient can be passively rotated externally and is here reported in degrees.
|
Pre-operative, 5 years follow-up
|
Radiographic Evaluation
Time Frame: Immediate post-operative, 6 weeks follow-up, 6 months follow-up, 1 year follow-up, 2 years follow-up, 3 years follow-up, 4 years follow-up, 5 years follow-up.
|
A complete radiographic evaluation (front view 3 rotations, lateral view) is completed pre-operatively.
For the post-operative radiographic evaluations, the form is simplified and contains two options: "unchanged" or "changed" when compared to the preoperative x-ray, with presence of radiolucencies and/or notching.
The number of "changed" radiographic evaluations per time point are here reported.
|
Immediate post-operative, 6 weeks follow-up, 6 months follow-up, 1 year follow-up, 2 years follow-up, 3 years follow-up, 4 years follow-up, 5 years follow-up.
|
Survivorship
Time Frame: 5 years follow-up
|
The Kaplan-Meier method is used to report implant survivorship.
This outcome measures survivorship of the implanted devices from the date of implantation to the date of revision or intended revision up to 5 years post-operatively.
|
5 years follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 20, 2010
Primary Completion (Actual)
December 31, 2015
Study Completion (Actual)
December 31, 2019
Study Registration Dates
First Submitted
January 29, 2018
First Submitted That Met QC Criteria
February 12, 2018
First Posted (Actual)
February 13, 2018
Study Record Updates
Last Update Posted (Actual)
October 19, 2021
Last Update Submitted That Met QC Criteria
September 21, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ORTHO.CR.E13
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on TESS V2
-
VA Office of Research and DevelopmentRecruitingSpinal Cord InjuryUnited States
-
Zimmer BiometRecruitingRheumatoid Arthritis | Osteonecrosis | Avascular Necrosis | Rotator Cuff Tears | Proximal Humeral Fracture | Osteoarthritis Shoulder | Rotator Cuff Tear Arthropathy | Rheumatoid Arthritis Shoulder | Revision | Malunion of Fracture, Shoulder RegionFrance
-
Joimax GmbHWithdrawnLumbar Disc HerniationAustria, Germany
-
Istituto Ortopedico RizzoliActive, not recruitingQuality of Life | Fatigue Syndrome, Chronic | Bone TumorItaly
-
Mustafa Kemal UniversityCompletedHealthy | Health, Subjective | Health Knowledge, Attitudes, PracticeTurkey
-
MarsiBionicsHospital General Universitario Gregorio Marañon; Hospital Infantil Universitario... and other collaboratorsCompletedCerebral Palsy | Acquired Brain Injury | Neuromuscular Diseases in ChildrenSpain
-
University of FloridaFlorida Breast Cancer FoundationCompletedBreast CancerUnited States
-
Western Galilee Hospital-NahariyaUniversity of HaifaCompleted
-
Medical University of South CarolinaCompleted
-
Iraqi Board of medical specialtiesCompletedTrigeminal NeuralgiaIraq